Finance

Lists
HYPE3:BVMF
Hypera SA
R$26,93
0,00%
(0,00) 1D
9 Okt., 17:05:47 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for HYPE3...
Open
R$26,96
High
R$27,25
Low
R$26,51
Mkt. cap
18,96 mjd
Avg. vol.
3,90 m
Volume
5,65 m
Dividend
3,56%
Quarterly dividend
R$0,24
Ex-dividend date
09 Feb. 2026
P/E ratio
10,14
52-wk high
R$30,00
52-wk low
R$19,43
EPS
R$2,66
Shares outstanding
704,01 m
No. of employees
11 k
Open
R$26,96
High
R$27,25
Low
R$26,51
Mkt. cap
18,96 mjd
Avg. vol.
3,90 m
Volume
5,65 m
Dividend
3,56%
Quarterly dividend
R$0,24
Ex-dividend date
09 Feb. 2026
P/E ratio
10,14
52-wk high
R$30,00
52-wk low
R$19,43
EPS
R$2,66
Shares outstanding
704,01 m
No. of employees
11 k
News stories
From web sources and news partners
Profile
Hypera Pharma is a Brazilian multinational pharmaceutical company and is the largest Brazilian pharmaceutical company by market capitalization. Headquartered in São Paulo, its business include pharmaceuticals, consumer healthcare and cosmetics products, and biotechnology products. Wikipedia
About Hypera SA
CEO-
Employees10,6 k
Founded2001
HeadquartersItaim Bibi, São Paulo, Brasilië
SectorPharmaceutical industry
Last report
07 Aug. 2026
Fiscal period
Q2 2026
R$0,70 / R$0,70
-0,54%miss
Revenue / Est. (BRL)
2,34 mjd / 2,33 mjd
+0,28%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in BRL
Loading Previous Earnings...
Revenue
Net income
All values in BRL
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
2,23 mjd
2,24 mjd
2,02 mjd
2,34 mjd
Cost of goods sold
865,21 m
858,94 m
807,22 m
892,99 m
Cost of revenue
865,21 m
858,94 m
807,22 m
892,99 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
687,46 m
728,46 m
703,28 m
780,69 m
Operating expense
688,45 m
728,74 m
701,06 m
773,84 m
Total operating expenses
1,55 mjd
1,59 mjd
1,51 mjd
1,67 mjd
Operating income
673,59 m
649,38 m
509,50 m
669,87 m
Other non operating income
-14,67 m
-27,28 m
-8,73 m
-30,17 m
EBT including unusual items
448,11 m
439,21 m
276,14 m
492,29 m
EBT excluding unusual items
452,42 m
438,30 m
279,75 m
488,66 m
Income tax expense
-5,77 m
-10,46 m
-69,54 m
2,28 m
Effective tax rate
-1,29%
-2,38%
-25,18%
0,46%
Other operating expenses
987,00 k
283,00 k
-2,21 m
-6,84 m
Net income
457,64 m
450,99 m
347,38 m
490,24 m
Net profit margin
20,55%
20,16%
17,22%
20,98%
Earnings per share
0,72
0,71
0,55
0,70
Interest and investment income
69,23 m
68,87 m
64,66 m
63,02 m
Interest expense
-283,65 m
-268,84 m
-282,34 m
-209,57 m
Net interest expenses
-214,42 m
-199,97 m
-217,68 m
-146,55 m
Depreciation and amortization charges
-
-
-
-
EBITDA
728,99 m
702,34 m
562,68 m
755,79 m
Gain or loss from assets sale
-11,00 k
-253,00 k
-3,20 m
-698,00 k
AI content may include mistakes. Learn more
Google-programme